Please ensure Javascript is enabled for purposes of website accessibility

Is MedMen Enterprises a Buy?

By Billy Duberstein - May 16, 2019 at 7:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

We're seeing a lot of smoke around the company. Is there fire?

MedMen Enterprises (MMNFF -4.55%) has been one of the more controversial cannabis stocks out there. On the positive side, the company's California stores generate huge sales, besting even Apple stores in sales per square foot. The company also recently lured Spike Jonze to make an ad for it. In addition, MedMen is aggressively ramping up production and opening dispensaries, started its own magazine called EMBER, and recently introduced its own private-label brand, Statemade.

On the other hand, the company is also massively unprofitable and is diluting shareholders as it aggressively expands across the U.S. This could theoretically lead to high upside but also carries a high amount of risk. However, it's another troubling element that has me staying well clear of MedMen's stock today.

MedMen CEO Adam Bierman speaks at a podium in front of a construction site next to a MedMen flag.

MedMen CEO Adam Bierman. Image source:

Employees leaving -- and suing

The trouble started last November, when ex-CFO James Parker "resigned" from MedMen after just a year on the job. Parker would later go on to file a lawsuit against MedMen, claiming he was essentially forced to resign because he wouldn't do things he deemed unethical.

Parker's allegations accuse CEO Adam Bierman and President Andrew Modlin of asking him to:

  • Sign off on lavish personal expenditures, such as hiring Bierman's personal therapist as a "company performance coach" and purchasing a custom $160,000 Tesla for Modlin. 
  • Wire money to a consultant in Canada to prop the stock up when it was under attack.
  • Dig up dirt on personal enemies.
  • Refuse to correct a press release.
  • Make a donation toward a favored political candidate.

Parker also alleged that the founders presided over a culture that was "replete with racial, homophobic and misogynistic epithets and slurs."

But wait, there's more! Just last month, MedMen became the target of a second lawsuit, this time from early investor MMMG-MC Inc., an investment company run by principals Brent Cox and Omar Mangalji. They allege Bierman and Modlin sold shares during a period when early investors were under lockup, meaning they were restricted from selling shares just after the IPO.

Then, just on April 19, MedMen announced three more senior executive departures: Chief Operating Officer Ben Cook, General Counsel Lisa Sergi, and Senior Vice President of Corporate Communications Daniel Yi. However, the company also announced a new hire, CTO Ryan Lissack.

In their defense

As is to be expected, Bierman and Modlin categorically denied all allegations. It was actually Yi (who is no longer there) who wrote a response to Parker's suit back in the early part of the year: "James Parker worked at MedMen for less than a year and half, quit and is now demanding more than $22 million from the company while making wild allegations that have no basis in fact." Bierman was even more blunt in an interview, saying, "Parker's accusations are false. ... It is a meritless claim that will lose in court."

Former LA Mayor Antonio Villaraigosa, who is a MedMen board member, also defended Bierman and Modlin after the lawsuit came out, saying he "has full confidence in the leadership of Adam Bierman and Andrew Modlin to build the world's finest cannabis retailer."

On the subject of the MMMG-MC Inc. lawsuit, Bierman said the early shareholders' accusations were "patently false...we have already generated a tremendous return for them." (Notice that he doesn't answer the question about selling stock when others couldn't and just mentions early-investor profits.)

And management didn't have much to say on the recent executive departures, stating only that it had confidence in the new executive team, whose gaps will be filled by other team members, and that "the leaders of the operations group will now report directly to the CEO." So it appears that they are scrapping the COO position altogether, with the two founders more firmly in control.

Smoke or fire?

I don't necessarily think a disgruntled ex-employee filing a lawsuit automatically disqualifies a company from being investable. Unfortunately, we live in a litigious society, and people often target companies flush with cash in order to force million-dollar settlements.

However, there is an awful lot of smoke here, with three different incidents, and MedMen isn't exactly a known, blue-chip company with a long track record. The company is taking an aggressive approach to a pretty wild, unpredictable emerging industry. It's also losing about $60 million every single quarter as it "invests" in growth.

While any single allegation can be disputed on its merits (I'm sure other companies spend a fair amount on executive perks), the sheer number of lawsuits and departures at MedMen is enough to prevent me from buying. There are plenty of other exciting stocks out there, including even other pot stocks that don't have nearly the number of headaches.

But hey, it's certainly entertaining to watch from the sidelines.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MedMen Enterprises Stock Quote
MedMen Enterprises
$0.09 (-4.55%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.